Induction of pro-inflammatory cytokine production in thymocytes by the immune response modifiers Imiquimod and Gardiquimod™

International Immunopharmacology

Volumn 17, Issue 2, 2013, Pages 427-431

  Weber, Andreas ^a   Zimmermann, Corinna ^a   Mausberg, Anne K ^a   Kieseier, Bernd C ^a   Hartung, Hans Peter ^a   Hofstetter, Harald H ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Cytokine; Immune response modifier; Interleukin 17; T cell; Thymus

Indexed keywords

ANTIVIRUS AGENT; GAMMA INTERFERON; GARDIQUIMOD; IMIQUIMOD; INTERLEUKIN 17; INTERLEUKIN 6; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYMOCYTE;

CYTOKINE; IMMUNE RESPONSE MODIFIER; INTERLEUKIN 17; T CELL; THYMUS;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELLS, CULTURED; DRUG SYNERGISM; FEMALE; IMIDAZOLES; INFECTION; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; INTERLEUKIN-6; MICE; MICE, INBRED C57BL; NEOPLASMS; THYMOCYTES;

EID: 84881524257     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2013.06.023     Document Type: Article

References (23)

1. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol 2009;27:485-517.
2. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6:1123-32. (Pubitemid 41541790)
3. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;6:1133-41. (Pubitemid 41541791)
4. Hofstetter HH, Luhder F, Toyka KV, Gold R. IL-17 production by thymocytes upon CD3 stimulation and costimulation with microbial factors. Cytokine 2006;34: 184-97. (Pubitemid 44038574)
5. Kim JS, Smith-Garvin JE, Koretzky GA, Jordan MS. The requirements for natural Th17 cell development are distinct from those of conventional Th17 cells. J Exp Med 2011;208:2201-7.
6. Marks BR, Nowyhed HN, Choi JY, Poholek AC, Odegard JM, Flavell RA, et al. Thymic self-reactivity selects natural interleukin 17-producing T cells that can regulate peripheral inflammation. Nat Immunol 2009;10:1125-32.
7. Tanaka S, Yoshimoto T, Naka T, Nakae S, Iwakura Y, Cua D, et al. Natural occurring IL-17 producing T cells regulate the initial phase of neutrophil mediated airway responses. J Immunol 2009;183:7523-30.
8. Smolianov V, Dehmel T, Kieseier BC, Hemmer B, Hartung HP, Hofstetter HH. Ex vivo activation of naturally occurring IL-17-producing T cells does not require IL-6. Cytokine 2012;58:231-7.
9. Hofmann J,Mair F,GreterM, Schmidt-SupprianM, Becher B.NIK signaling in dendritic cells but not in T cells is required for the development of effector T cells and cell-mediated immune responses. J Exp Med 2011;208:1917-29.
10. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335-76. (Pubitemid 37174535)
11. Nishiya T, DeFranco AL. Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the Toll-like receptors. J Biol Chem 2004;279:19008-17. (Pubitemid 38623331)
12. Ma F, Zhang J, Zhang C. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice. Cell Mol Immunol 2010;7: 381-8.
13. Schon MP, Schon M. TLR7 and TLR8 as targets in cancer therapy. Oncogene 2008;27:190-9.
14. TerlouA, van SetersM, KleinjanA, Heijmans-Antonissen C, Santegoets LA, BeckmannI, et al. Imiquimod-induced clearance ofHPV is associated with normalization of immune cell counts in usual type vulvar intraepithelial neoplasia. Int J Cancer 2010;127: 2831-40.
15. Perkins N, Nisbet M, Thomas M. Topical imiquimod treatment of aciclovir-resistant herpes simplex disease: case series and literature review. Sex Transm Infect 2011;87:292-5.
16. Xiong Z, Ohlfest JR. Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors. J Immunother 2011;34:264-9.
17. Lee J, Chuang TH, Redecke V, She L, Pitha PM, Carson DA, et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci U S A 2003;100:6646-51. (Pubitemid 36666635)
18. Fletcher S, Steffy K, Averett D.Masked oral prodrugs of toll-like receptor 7 agonists: a new approach for the treatment of infectious disease. Curr Opin Investig Drugs 2006;7:702-8. (Pubitemid 44263174)
19. Pantelyushin S, Haak S, Ingold B, Kulig P, Heppner FL, Navarini AA, et al. Rorgammat+ innate lymphocytes and gammadelta T cells initiate psoriasiform plaque formation in mice. J Clin Invest 2012;122:2252-6.
20. Baenziger S, Heikenwalder M, Johansen P, Schlaepfer E, Hofer U, Miller RC, et al. Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. Blood 2009;113:377-88.
21. Koerner P, Traeger T,Mehmcke H, Cziupka K, KesslerW, Busemann A, et al. Stimulation of TLR7 prior to polymicrobial sepsis improves the immune control of the inflammatory response in adult mice. Inflamm Res 2011;60:271-9.
22. Billard MJ, Gruver AL, Sempowski GD. Acute endotoxin-induced thymic atrophy is characterized by intrathymic inflammatory and wound healing responses. PLoS One 2011;6:e17940.
23. Wang SD, Huang KJ, Lin YS, Lei HY. Sepsis-induced apoptosis of the thymocytes in mice. J Immunol 1994;152:5014-21.